The prognostic value of quantitative analysis of CCL5 and collagen IV in luminal B (HER2−) subtype breast cancer by quantum-dot-based molecular imaging

References

• DeSantisCEMaJGoding SauerANewmanLAJemalABreast cancer statistics, 2017, racial disparity in mortality by stateCA Cancer J Clin201767643944828972651
   PubMed Web of Science ®Google Scholar
• YanagawaMIkemotKKawauchiSLuminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotypeBMC Res Notes2012537622830453
   PubMedGoogle Scholar
• FockeCMvan DiestPJDeckerTSt Gallen 2015 subtyping of luminal breast cancers: impact of different Ki67-based proliferation assessment methodsBreast Cancer Res Treat201615921727460637
   PubMed Web of Science ®Google Scholar
• EffiABAmanNAKouiBSKoffiKDTraoreZCKouyateMBreast cancer molecular subtypes defined by ER/PR and HER2 status: association with clinicopathologic parameters in Ivorian patientsAsian Pac J Cancer Prev20161741973197827221883
   PubMedGoogle Scholar
• HolowatyjANRuterbuschJJRatnamMGorskiDHCoteMLHER2 status and disparities in luminal breast cancersCancer Med2016582109211627250116
   PubMed Web of Science ®Google Scholar
• BediagaNGBeristainECalvoBLuminal B breast cancer subtype displays a dicotomic epigenetic patternSpringerplus20165111026759740
   PubMedGoogle Scholar
• LiZHHuPHTuJHYuNSLuminal B breast cancer: patterns of recurrence and clinical outcomeOncotarget2016740650246503327542253
   PubMedGoogle Scholar
• KnudsenESWitkiewiczAKDefining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2− breast cancerOncotarget2016743691116912327564114
   PubMedGoogle Scholar
• ParkCParkKKimJPrognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancerWorld J Surg Oncol201614124427619909
   PubMedGoogle Scholar
• RajcJGugićDFröhlichIMarjanovićKDumenčićBPrognostic role of nectin-4 expression in luminal B (HER2 negative) breast cancerPathol Res Pract201721391102110828778498
   PubMed Web of Science ®Google Scholar
• CancelloGMaisonneuvePRotmenszNProgesterone receptor loss identifies luminal B breast cancer subgroups at higher risk of relapseAnn Oncol201324366166823022996
   PubMed Web of Science ®Google Scholar
• MiyagawaYMiyakeTYanaiAAssociation of body mass index with risk of luminal A but not luminal B estrogen receptor-positive and HER2-negative breast cancer for postmenopausal Japanese womenBreast Cancer201522439940524000037
   PubMed Web of Science ®Google Scholar
• CriscitielloCDisalvatoreDDe LaurentiisMHigh Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancerBreast2014231697524314620
   PubMed Web of Science ®Google Scholar
• MaisonneuvePDisalvatoreDRotmenszNProposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypesBreast Cancer Res2014163R6524951027
   PubMed Web of Science ®Google Scholar
• ZongYZhuLWuJProgesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective studyPLoS One201498e9562925170613
   PubMed Web of Science ®Google Scholar
• SatoKMiyashitaMIshidaTPrognostic significance of the progesterone receptor status in Ki67-high and -low luminal B-like HER2-negative breast cancersBreast Cancer201623231031725380989
   PubMed Web of Science ®Google Scholar
• CampbellMJBaehnerFO’MearaTCharacterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breastBreast Cancer Res Treat20171611172827785654
   PubMed Web of Science ®Google Scholar
• ChengKKDicksonAGujamFJMcMillanDCEdwardsJThe relationship between oestrogen receptor-alpha phosphorylation and the tumour microenvironment in patients with primary operable ductal breast cancerHistopathology201770578279727891654
   PubMed Web of Science ®Google Scholar
• WuXLiuHLiuJImmunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dotsNat Biotechnol2003211414612459735
   PubMed Web of Science ®Google Scholar
• ChenCPengJXiaHQuantum-dot-based immunofluorescent imaging of HER2 and ER provides new insights into breast cancer heterogeneityNanotechnology201021909510120110584
   PubMed Web of Science ®Google Scholar
• YangXQChenCPengCWQuantum dot-based quantitative immunofluorescence detection and spectrum analysis of epidermal growth factor receptor in breast cancer tissue arraysInt J Nanomedicine201162265227322072864
   PubMed Web of Science ®Google Scholar
• SunJZChenCJiangGTianWQLiYSunSRQuantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast cancerInt J Nanomedicine201491339134624648732
   PubMed Web of Science ®Google Scholar
• PengCWLiuXLChenCPatterns of cancer invasion revealed by QDs-based quantitative multiplexed imaging of tumor microenvironmentBiomaterials201132112907291721262536
   PubMed Web of Science ®Google Scholar
• LiuXLPengCWChenCQuantum dots-based double-color imaging of HER2 positive breast cancer invasionBiochem Biophys Res Commun2011409357758221609713
   PubMed Web of Science ®Google Scholar
• MiZBhattacharyaSDKimVMGuoHTalbotLJKuoPCOsteo-pontin promotes CCL5-mesenchymal stromal cell mesenchymal stromal cell-mediated breast cancer metastasisCarcinogenesis201132447748721252118
   PubMed Web of Science ®Google Scholar
• ForstBHansenMTKlingelhöferJMetastasis-inducing S100A4 and RANTES cooperate in promoting tumor progression in micePLoS One201054e1037420442771
   PubMed Web of Science ®Google Scholar
• RizviSBRouhiSTaniguchiSNear-infrared quantum dots for HER2 localization and imaging of cancer cellsInt J Nanomedicine201491323133724648731
   PubMed Web of Science ®Google Scholar
• MichalskaMFlorczakADams-KozlowskaHGapinskiJJurgaSSchneiderRPeptide-functionalized ZCIS QDs as fluorescent nanoprobe for targeted HER2-positive breast cancer cells imagingActa Biomater20163529330426850146
   PubMed Web of Science ®Google Scholar
• XuHChenCPengJEvaluation of the bioconjugation efficiency of different quantum dots as probes for immunostaining tumor-marker proteinsAppl Spectrosc201064884785220719046
   PubMed Web of Science ®Google Scholar
• ChenCSunSRGongYPQuantum dots-based molecular classification of breast cancer by quantitative spectroanalysis of hormone receptors and HER2Biomaterials201132307592759921745686
   PubMed Web of Science ®Google Scholar
• VelaeiKSamadiNBarazvanBSoleimani RadJTumor microenvironment-mediated chemoresistance in breast cancerBreast2016309210027668856
   PubMed Web of Science ®Google Scholar
• WeitzenfeldPMeshelTBen-BaruchAMicroenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in luminal-A breast tumor cellsOncotarget2016749811238114327835603
   PubMedGoogle Scholar
• ChenXWangYNelsonDCCL2/CCR2 regulates the tumor microenvironment in HER-2/neu-driven mammary carcinomas in micePLoS One20161111e016559527820834
   PubMed Web of Science ®Google Scholar
• SvenssonSAbrahamssonARodriguezGVCCL2 and CCL5 are novel therapeutic targets for estrogen-dependent breast cancerClin Cancer Res201521163794380525901081
   PubMed Web of Science ®Google Scholar
• YiEHLeeCSLeeJKSTAT3-RANTES autocrine signaling is essential for tamoxifen resistance in human breast cancer cellsMol Cancer Res2013111314223074171
   PubMed Web of Science ®Google Scholar
• NiwaYAkamatsuHNiwaHSumiHOzakiYAbeACorrelation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancerClin Cancer Res20017228528911234881
   PubMed Web of Science ®Google Scholar
• Yaal-HahoshenNShinaSLeider-TrejoLThe chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patientsClin Cancer Res200612154474448016899591
   PubMed Web of Science ®Google Scholar
• BiècheILereboursFTozluSEspieMMartyMLidereauRMolecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signatureClin Cancer Res200410206789679515501955
   PubMed Web of Science ®Google Scholar
• VittoriaDDomenicoLRosariaAMAdipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5Oncotarget2016717244952450927027351
   PubMedGoogle Scholar
• GaoDRahbarRFishENCCL5 activation of CCR5 regulates cell metabolism to enhance proliferation of breast cancer cellsOpen Biol20166616012227335323
   PubMed Web of Science ®Google Scholar
• YasuharaRIriéTSuzukiKThe β-catenin signaling pathway induces aggressive potential in breast cancer by up-regulating the chemokine CCL5Exp Cell Res20153381223126363360
   PubMed Web of Science ®Google Scholar
• ZhangQQinJZhongLCCL5-mediated Th2 immune polarization promotes metastasis in luminal breast cancerCancer Res201575204312432126249173
   PubMed Web of Science ®Google Scholar
• ReigosaAHardissonDSanziFCharacterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2− and ER+HER2+) breast cancersJ Steroid Biochem Mol Biol2017170657427154416
   PubMed Web of Science ®Google Scholar
• ReigosaAHardissonDSanziFCaleirasESaldiviaFFernándezASubclassification of the molecular types of breast cancer based on the expression of immunohistochemical markers and evolutionInvest Clin201657218721628429898
   PubMed Web of Science ®Google Scholar
• PendharkarNGajbhiyeATaunkKQuantitative tissue proteomic investigation of invasive ductal carcinoma of breast with luminal B HER2positive and HER2 enriched subtypes towards potential diagnostic and therapeutic biomarkersJ Proteomics201613211213026642762
   PubMed Web of Science ®Google Scholar
• OhlundDLundinCArdnorBOmanMNarediPSundMType IV collagen is a tumour stroma-derived biomarker for pancreas cancerBr J Cancer20091011919719491897
   PubMed Web of Science ®Google Scholar
• CavoMFatoMPeñuelaLBeltrameFRaiteriRScaglioneSMicroenvironment complexity and matrix stiffness regulate breast cancer cell activity in a 3D in vitro modelSci Rep201663536727734939
   PubMed Web of Science ®Google Scholar
• ChanNWillisAKornhauserNInfluencing the tumor microenvironment: phase 2 study of copper depletion with tetrathiomolybdate in high risk breast cancer and preclinical models of lung metastasesClin Cancer Res201723366667627769988
   PubMed Web of Science ®Google Scholar
• OkabeMTohUIwakumaNPredictive factors of tumor immune microenvironment for long-term follow-up in early stage breast cancerCancer Sci201610818190
   Web of Science ®Google Scholar